Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 9 von 267
Experimental biology and medicine (Maywood, N.J.), 2008-02, Vol.233 (2), p.200-208
2008

Details

Autor(en) / Beteiligte
Titel
Propofol Depresses Angiotensin II–Induced Cardiomyocyte Hypertrophy In Vitro
Ist Teil von
  • Experimental biology and medicine (Maywood, N.J.), 2008-02, Vol.233 (2), p.200-208
Ort / Verlag
London, England: SAGE Publications
Erscheinungsjahr
2008
Link zum Volltext
Quelle
EZB Free E-Journals
Beschreibungen/Notizen
  • Cardiomyocyte hypertrophy is formed in response to pressure or volume overload, injury, or neurohormonal activation. The most important vascular hormone that contributes to the development of hypertrophy is angiotensin II (Ang II). Accumulating studies have suggested that reactive oxygen species (ROS) may play an important role in cardiac hypertrophy. Propofol is a general anesthetic that possesses antioxidant action. We therefore examined whether propofol inhibited Ang II–induced cardiomyocyte hypertrophy. Our results showed that both ROS formation and hypertrophic responses induced by Ang II in cardiomyocytes were partially blocked by propofol. Further studies showed that propofol inhibited the phophorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) and mitogen-activated protein kinase/ERK kinase 1/2 (MEK1/2) induced by Ang II via a decrease in ROS production. In addition, propofol also markedly attenuated Ang II–stimulated nuclear factor-κB (NF-κB) activation via a decrease in ROS production. In conclusion, propofol prevents cardiomyocyte hypertrophy by interfering with the generation of ROS and involves the inhibition of the MEK/ERK signaling transduction pathway and NF-κB activation.

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX